Evercore ISI raised the firm’s price target on Abbott (ABT) to $136 from $128 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025
- 3 “Strong Buy” Dividend Aristocrat Stocks to Consider for the Long Term
- Abbott, DexCom settlement ‘not a complete surprise,’ says Wells Fargo
- DexCom, Abbott agree to settle patent litigation
- Abbott increases quarterly dividend 7.3% to 59c per share